Viral Vectors for Non-human Primates Market Revenue to Attain USD 359.87 Mn by 2033

24 Jun 2025

Share :

Table of Content

1. Viral Vectors for Non-human Primates Market Revenue and Trends 2025 to 2033 2. Exploring the Growth Potential of the Market 3. Segment Outlook 4. Regional Insights 5. Viral Vectors for Non-human Primates Market Coverage 6. Viral Vectors for Non-human Primates Market Key Players

Viral Vectors for Non-human Primates Market Revenue and Trends 2025 to 2033

The global viral vectors for non-human primate market revenue surpassed USD 161.2 million in 2025 and is predicted to attain around USD 359.87 million by 2033, growing at a CAGR of 10.56%. The growth of the market is attributed to the increasing demand for reliable preclinical models in gene therapy and neuroscience, where NHP’s offer unparalleled physiology that mimic human biology.

Exploring the Growth Potential of the Market

The viral vectors for non-human primates market is experiencing robust growth, driven by a rise in preclinical gene therapy studies and the ongoing need for translational models in neuroscience and infectious disease research. The physiological similarities of non-human primates (NHPs) compared to humans have made them essential to validating viral vectors' efficacy and safety. The rising development of improved AAV and lentiviral vectors engineered to target specific cell types is expanding the scope of applications for non-human primates. Moreover, governmental support for ethical primate research boosted the adoption of viral vectors in non-human primate models. Rising investments in biotechnology research create immense opportunities in the market.

Segment Outlook

• By vector type, the adeno-associated vectors (AAV) segment held the largest share of the market in 2024 owing to their low immunogenicity and ability to efficiently deliver genes to tissues and cells, making them suitable for neurological research.
• By type of non-human primates, the rhesus macaques segment led the market by capturing the largest share in 2024. Rhesus macaques are the best non-human primate model since they are genetically similar to humans, making them ideal for preclinical gene therapy and neuroscience research.
• By application, the gene therapy segment captured the biggest share of the market in 2024. This is mainly due to the increased pipeline of gene therapy, creating the need for effective viral vectors.
• By therapeutic area, the oncology disorders segment dominated the market in 2024 due to the increased development of novel gene therapy and research on cancer, creating the need for NHPs in modeling tumor biology and treatment efficacy.
• By end-user, the pharmaceutical and biotechnology companies segment led the market with a major revenue share in 2024. This is mainly due to increased R&D investments, advancements in gene therapy, and increased reliance on NHP models for preclinical validation.

Regional Insights

North America registered dominance in the viral vectors for non-human primates market due to the increased investment in biotechnology research. Rising government funding for R&D and high demand for gene therapy ensure the long-term growth of the market.

Asia Pacific is expected to grow at the fastest rate in the upcoming period. The growth of the market in the region is attributed to the increasing cancer research to develop novel cancer therapeutics, boosting the need for viral vectors in preclinical studies using NHPs. Countries such as China, Japan, and India are investing heavily in developing gene therapies, contributing to regional market growth.

Viral Vectors for Non-human Primates Market Coverage

Recent Developments

• In March 2025, researchers in Japan successfully used a nonviral system to introduce a transgene, a gene that has been artificially inserted into an organism, into cynomolgus monkeys, which is a species of primate closely related to humans.
  (Source: https://www.technologynetworks.com)
• In January 2024, N4 Pharma Plc is pleased to provide a further successful update on its ongoing research work into the use of Nuvec to enhance the performance of viral vectors. Through its research program with the University of Brunel, the Company has demonstrated via a series of in vitro experiments that Nuvec can deliver increased transduction efficacy, when complexed with Adeno-Associated virus 8 ("AAV8").
  (Source: https://www.investormeetcompany.com)

Viral Vectors for Non-human Primates Market Key Players

• Merck KGaA
• 4D Molecular Therapeutics
• Barinthus Biotherapeutics
• Biovian Oy
• Andelyn Biosciences
• Lonza Group AG
• Fujifilm Diosynth Biotechnologies
• CRISPR Therapeutics
• Oxford Biomedica
• REGENXBIO Inc.

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/6278

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com|+1 804 441 9344